Prognostic Nutritional Index is Related to All-Cause Mortality in Patients With Stage IV Colorectal Cancer Treated With Capecitabine: Single-Center 24-Month Observational Study in Vietnam

IF 2.6 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2024-10-08 DOI:10.1002/jcla.25112

Hung Nguyen Quang, Luan Nguyen Duc, Hieu Hoang Van, Hai Vu Anh, Kien Nguyen Trung, Thang Le Viet

{"title":"Prognostic Nutritional Index is Related to All-Cause Mortality in Patients With Stage IV Colorectal Cancer Treated With Capecitabine: Single-Center 24-Month Observational Study in Vietnam","authors":"Hung Nguyen Quang, Luan Nguyen Duc, Hieu Hoang Van, Hai Vu Anh, Kien Nguyen Trung, Thang Le Viet","doi":"10.1002/jcla.25112","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To determine the mortality rate and the predictive value of the prognostic nutritional index (PNI) for all-cause mortality during the 24 months in patients with stage IV colorectal cancer treated with capecitabine.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a study on 87 stage IV colorectal cancer patients treated with capecitabine. Before the day of treatment, all patients were measured CEA and CRP-hs levels and calculated neutrophil/lympho ratio (NLR) and PNI. Patients were monitored and collected drug side effects and mortality for 24 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The mortality rate of study subjects was 60.9%. CRP-hs, NLR, and PNI were independent factors associated with 24-month mortality in patients with stage IV colorectal cancer (<i>p</i> < 0.05 to <i>p</i> < 0.01). At a cut-off value of 38.51, PNI was a predictor for mortality, with the area under the curve (AUC) of 0.88 and <i>p</i> < 0.001.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PNI was a good predictor of all-cause mortality in patients with stage IV colorectal cancer treated with capecitabine for 24 months.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"38 21","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555609/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.25112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To determine the mortality rate and the predictive value of the prognostic nutritional index (PNI) for all-cause mortality during the 24 months in patients with stage IV colorectal cancer treated with capecitabine.

Methods

We conducted a study on 87 stage IV colorectal cancer patients treated with capecitabine. Before the day of treatment, all patients were measured CEA and CRP-hs levels and calculated neutrophil/lympho ratio (NLR) and PNI. Patients were monitored and collected drug side effects and mortality for 24 months.

Results

The mortality rate of study subjects was 60.9%. CRP-hs, NLR, and PNI were independent factors associated with 24-month mortality in patients with stage IV colorectal cancer (p < 0.05 to p < 0.01). At a cut-off value of 38.51, PNI was a predictor for mortality, with the area under the curve (AUC) of 0.88 and p < 0.001.

Conclusions

PNI was a good predictor of all-cause mortality in patients with stage IV colorectal cancer treated with capecitabine for 24 months.

Abstract Image

查看原文本刊更多论文

预后营养指数与接受卡培他滨治疗的 IV 期结直肠癌患者的全因死亡率相关：越南单中心 24 个月观察研究》。

目的：确定接受卡培他滨治疗的 IV 期结直肠癌患者在 24 个月内的死亡率以及预后营养指数（PNI）对全因死亡率的预测价值：我们对87名接受卡培他滨治疗的IV期结直肠癌患者进行了研究。在治疗前一天，所有患者均测量了 CEA 和 CRP-hs 水平，并计算了中性粒细胞/淋巴细胞比率（NLR）和 PNI。对患者进行24个月的监测，并收集药物副作用和死亡率的数据：研究对象的死亡率为 60.9%。CRP-hs、NLR和PNI是与IV期结直肠癌患者24个月死亡率相关的独立因素（P 结论：PNI是预测IV期结直肠癌患者24个月死亡率的良好指标：PNI 是预测接受卡培他滨治疗 24 个月的 IV 期结直肠癌患者全因死亡率的良好指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.